Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...
Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...
Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...
Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel, Feb.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果